{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T19:47:39Z","timestamp":1770061659985,"version":"3.49.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2001,7,1]],"date-time":"2001-07-01T00:00:00Z","timestamp":993945600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":6750,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2001,7]]},"DOI":"10.1023\/a:1011165115426","type":"journal-article","created":{"date-parts":[[2002,12,23]],"date-time":"2002-12-23T11:26:45Z","timestamp":1040642805000},"page":"967-974","source":"Crossref","is-referenced-by-count":31,"title":["Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: An EORTC Gynecological Cancer Cooperative Group study"],"prefix":"10.1016","volume":"12","author":[{"given":"J.B.","family":"Vermorken","sequence":"first","affiliation":[]},{"given":"G.","family":"Zanetta","sequence":"additional","affiliation":[]},{"given":"C.F.","family":"De Oliveira","sequence":"additional","affiliation":[]},{"given":"M.E.L.","family":"van der Burg","sequence":"additional","affiliation":[]},{"given":"A.J.","family":"Lacave","sequence":"additional","affiliation":[]},{"given":"I.","family":"Teodorovic","sequence":"additional","affiliation":[]},{"given":"G. Hoctin","family":"Boes","sequence":"additional","affiliation":[]},{"given":"N.","family":"Colombo","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1023\/A:1011165115426_bb0010","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1046\/j.1525-1438.1993.03030129.x","article-title":"The role of chemotherapy in squamous cell carcinoma of the uterine cervix: A review","volume":"3","author":"Vermorken","year":"1993","journal-title":"Int J Gynecol Cancer"},{"key":"10.1023\/A:1011165115426_bb0015","first-page":"373","article-title":"Chemotherapy in cervical carcinoma","volume":"9","author":"Muscato","year":"1982","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1011165115426_bb0020","first-page":"229","article-title":"Chemotherapy of cervical cancer","volume":"12","author":"Guthrie","year":"1985","journal-title":"Clin Obstet Gynecol"},{"key":"10.1023\/A:1011165115426_bb0025","first-page":"89","article-title":"Die Chemotherapie des fortgeschrittenen Zervixkarzinoms. Ein \u00dcberblick","volume":"7","author":"Umbach","year":"1986","journal-title":"Tumor Diagn Ther"},{"issue":"Suppl 3","key":"10.1023\/A:1011165115426_bb0030","first-page":"11","article-title":"Cisplatin in advanced cancer of the cervix: An update","volume":"18","author":"Alberts","year":"1991","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1011165115426_bb0035","first-page":"54","article-title":"Chemotherapy for cervix cancer","volume":"21","author":"Omura","year":"1994","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1011165115426_bb0040","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1056\/NEJM199604183341606","article-title":"Cancer of the uterine cervix","volume":"334","author":"Cannistra","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1023\/A:1011165115426_bb0045","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0305-7372(98)90069-X","article-title":"Chemotherapy in squamous cell carcinoma of the cervix uteri. Present role and perspectives","volume":"24","author":"Pignata","year":"1998","journal-title":"Cancer Treat Rev"},{"key":"10.1023\/A:1011165115426_bb0050","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1200\/JCO.1985.3.8.1079","article-title":"Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: A Gynecologic Oncology Group Study","volume":"3","author":"Bonomi","year":"1985","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011165115426_bb0055","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0090-8258(89)80033-2","article-title":"A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix A Gynecologic Oncology Group study","volume":"32","author":"Thigpen","year":"1989","journal-title":"Gynecol Oncol"},{"key":"10.1023\/A:1011165115426_bb0060","first-page":"125","article-title":"EORTC-GCCG phase II trials in disseminated cancer of the uterine cervix","volume":"10","author":"Vermorken","year":"1985","journal-title":"Gin Med Repr"},{"key":"10.1023\/A:1011165115426_bb0065","first-page":"208","article-title":"Bleomycin (B), vindesine (E), mitomycin-C (M) and cisplalin (P) in recurrent and\/or metastatic squamous cell carcinoma of the uterine cervix (SCCUC): A phase II study of the EORTC Gynecological Cancer Cooperative Group (GCCG)","volume":"4","author":"Vermorken","year":"1987","journal-title":"Proc Eur Conf Clin Oncol"},{"key":"10.1023\/A:1011165115426_bb0070","first-page":"31","article-title":"Mitomycin-C\/cisplatin (MP) based combination chemotherapy in recurrent and\/or metastatic squamous cell carcinoma of the uterine cervix (SCCUC): The EORTC Gynecological Cancer Cooperative Group experience","volume":"1","author":"Vermorken","year":"1987","journal-title":"Proc Int Gynecol Cancer Soc Meet"},{"key":"10.1023\/A:1011165115426_bb0075","first-page":"313","article-title":"Mitomycin-C, bleomycin, vincristine, and cis-platinum in the treatment of advanced, recurrent squamous cell carcinoma of the cervix","volume":"4","author":"Alberts","year":"1981","journal-title":"Cancer Clin Trials"},{"key":"10.1023\/A:1011165115426_bb0080","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/1097-0142(19890401)63:7<1283::AID-CNCR2820630709>3.0.CO;2-U","article-title":"Factors affecting the response of recurrent squamous cell carcinoma of the cervix to cisplatin","volume":"63","author":"Potter","year":"1989","journal-title":"Cancer"},{"key":"10.1023\/A:1011165115426_bb0085","series-title":"WHO Handbook for Reporting Results of Cancer Treatments","author":"World Health Organization","year":"1979"},{"key":"10.1023\/A:1011165115426_bb0090","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1200\/JCO.1987.5.11.1791","article-title":"Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: A Southwest Oncology Group Study","volume":"5","author":"Alberts","year":"1987","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011165115426_bb0095","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1200\/JCO.1997.15.1.165","article-title":"Randomized trial of cisplatin versus cisplatin plus mitolactol (Dibromodulcitol) versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: A Gynecologic Oncology Group Study","volume":"15","author":"Omura","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011165115426_bb0100","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1093\/jnci\/81.5.359","article-title":"Combination bleomycin, ifosfamide, and cisplatin chemotherapy in cervical cancer","volume":"81","author":"Buxton","year":"1989","journal-title":"J Natl Cancer Inst"},{"key":"10.1023\/A:1011165115426_bb0105","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0090-8258(91)90100-J","article-title":"Chemotherapy in recurrent and advanced cervical cancer","volume":"40","author":"Kumar","year":"1991","journal-title":"Gynecol Oncol"},{"key":"10.1023\/A:1011165115426_bb0110","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/j.1447-0756.1998.tb00115.x","article-title":"Single agent versus combination chemotherapy in recurrent cervical cancer","volume":"24","author":"Kumar","year":"1998","journal-title":"J Obstet Gynaecol Res"},{"key":"10.1023\/A:1011165115426_bb0115","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0090-8258(92)90256-I","article-title":"Trop\u00e9. Bleomycin\u2013ifosfamide\u2013cis-platinum (BIP) in pelvic recurrence of previously irradiated cervical carcinoma: A second look","volume":"46","author":"Ramm","year":"1992","journal-title":"Gynecol Oncol"},{"key":"10.1023\/A:1011165115426_bb0120","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1200\/JCO.1996.14.3.792","article-title":"Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study","volume":"14","author":"McGuire","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011165115426_bb0125","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00001813-199708000-00002","article-title":"An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix","volume":"8","author":"Kudelka","year":"1997","journal-title":"Anticancer Drugs"},{"key":"10.1023\/A:1011165115426_bb0130","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/00001813-199606000-00004","article-title":"Preliminary report of the activity of docetaxel in advanced or recurrent squamous cell cancer of the cervix","volume":"7","author":"Kudelka","year":"1996","journal-title":"Anticancer Drugs"},{"key":"10.1023\/A:1011165115426_bb0135","first-page":"224","article-title":"Late phase II study of CPT-II, a topoisomerase I inhibitor, in advanced cervical carcinoma","volume":"11","author":"Takeuchi","year":"1992","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1023\/A:1011165115426_bb0140","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1200\/JCO.1997.15.2.625","article-title":"Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix","volume":"15","author":"Verschraegen","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011165115426_bb0145","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1006\/gyno.1998.5129","article-title":"A phase II trial of CPT-II in recurrent squamous carcinoma of the cervix: A gynecologic Oncology Group study","volume":"70","author":"Look","year":"1998","journal-title":"Gynecol Oncol"},{"key":"10.1023\/A:1011165115426_bb0150","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/(SICI)1097-0142(19980115)82:2<334::AID-CNCR13>3.0.CO;2-#","article-title":"A phase II study of irinotecan (CPT-II) in patients with advanced squamous cell carcinoma of the cervix","volume":"82","author":"Irvin","year":"1998","journal-title":"Cancer"},{"key":"10.1023\/A:1011165115426_bb0155","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1200\/JCO.1999.17.10.3136","article-title":"Results of a European Organization for Research and Treatment of Cancer\/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix","volume":"17","author":"Lhomm\u00e9","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011165115426_bb0160","first-page":"280","article-title":"Phase II trial of topotecan for cervical cancer of the uterus","volume":"15","author":"Noda","year":"1996","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1023\/A:1011165115426_bb0165","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1200\/JCO.1998.16.3.1094","article-title":"Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix","volume":"16","author":"Morris","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011165115426_bb0170","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1200\/JCO.1997.15.2.604","article-title":"Vinorelbine as neoudjuvant chemotherapy in advanced cervical carcinoma","volume":"15","author":"Lacave","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011165115426_bb0175","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0959-8049(99)00237-3","article-title":"Phase II trial of vinorelbine in patients with advanced and\/or recurrent cervical carcinoma: An EORTC Gyneaecological Cancer Cooperative Group Study","volume":"36","author":"Lhomm\u00e9","year":"2000","journal-title":"Eur J Cancer"},{"key":"10.1023\/A:1011165115426_bb0180","first-page":"296","article-title":"Bezwoda WR. A phase II study of gemcitabine in advanced cervix carcinoma: Final data","volume":"15","author":"Goedhals","year":"1996","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1023\/A:1011165115426_bb0185","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1006\/gyno.1999.5671","article-title":"Evaluation of gemcitabine in patients with squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group","volume":"76","author":"Schilder","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1023\/A:1011165115426_bb0190","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1200\/JCO.1999.17.9.2676","article-title":"Paclitaxel and cisplatin us first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study","volume":"17","author":"Rose","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011165115426_bb0195","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.1999.17.3.761","article-title":"Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix","volume":"17","author":"Papadimitriou","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1011165115426_bb0200","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1023\/A:1008362814642","article-title":"Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer","volume":"10","author":"Zanetta","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1011165115426_bb0205","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/gyno.1999.5657","article-title":"A phase II study of gemcitabine and cisplatin in patients with advanced, persistent, or recurrent squamous cell carcinoma of the cervix","volume":"76","author":"Burnett","year":"2000","journal-title":"Gynecol Oncol"},{"key":"10.1023\/A:1011165115426_bb0210","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000012076","article-title":"Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer","volume":"58","author":"Sugiyama","year":"2000","journal-title":"Oncology"},{"key":"10.1023\/A:1011165115426_bb0215","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1200\/JCO.1998.16.5.1879","article-title":"Chemotherapy for cervical carcinoma: Factors determining response and implications for clinical trial design","volume":"16","author":"Brader","year":"1998","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419541837?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419541837?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/12\/7\/967\/19479593\/12-7-967.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T07:05:20Z","timestamp":1582182320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419541837"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,7]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2001,7]]}},"alternative-id":["S0923753419541837"],"URL":"https:\/\/doi.org\/10.1023\/a:1011165115426","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2001,7]]}}}